PBA-0111 / Pure Biologics - LARVOL DELTA

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Pure Biologics S.A. | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Head and Neck Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

PUR Conclusion of an annex to the term sheet regarding the sale transaction of projects PBA-0405 and PBA-0111 [Google translation] (Money.Pl) - "The Management Board of Pure Biologics S.A. with its registered office in Wrocław...with reference to current report no. 44/2024 dated September 16, 2024 on the signing of a term sheet document regarding the sale transaction of the PBA-0405 and PBA-0111 projects ['Term Sheet'], taking into account that work on concluding an agreement for the sale of rights to the above projects ['Transaction'] is highly advanced and in connection with the Extraordinary General Meeting of the Company convened for December 27, 2024, the agenda of which includes the adoption of a resolution on giving consent to the sale by the Company of rights to the PBA-0405 and PBA-0111 projects, informs that today an annex was concluded between the parties to the Term Sheet, in which the parties agree to extend the Transaction deadline until December 30, 2024."

Commercial • Hematological Malignancies • Solid Tumor

A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Pure Biologics S.A.

New P1 trial • Breast Cancer • Head and Neck Cancer • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • CASP3 • CD86 • GZMB • TNFA

PUR Conclusion of a term sheet regarding the sale transaction of projects PBA-0405 and PBA-0111 [Google translation] (Money.Pl) - "The Management Board of Pure Biologics S.A...hereby announces that on September 16, 2024, the Company signed a term sheet document regarding the sale of the PBA-0405 [PB004] and PBA-0111 [PB003G] projects to a company incorporated under American law ['Buyer'], which intends to continue the development of PBA-0405 and PBA-0111...According to the Term Sheet, the parties expect to conclude an agreement for the sale of rights to the projects within 90 days from the date of the Term Sheet. The Transaction Assumptions provide that for the sale of all rights to the PBA-0405 and PBA-0111 projects, the Company will be entitled to an initial fee ['Upfront'] in the amount of USD 4,000,000 to 4,500,000 for each project, i.e. in the total amount of USD 8,000,000 to 9,000,000....If the Transaction is concluded, the Company will present detailed plans for further development."

Licensing / partnership • Hematological Malignancies • Oncology • Solid Tumor